encequidar   Click here for help

GtoPdb Ligand ID: 12787

Synonyms: HM-30181 | HM30181 | Oratecan (encequidar methanesulfonate + irinotecan) | Oraxol (encequidar methanesulfonate + paclitaxel)
PDB Ligand
Compound class: Synthetic organic
Comment: Encequidar (HM30181) is an inhibitor of ATP-binding cassette (ABC) transporter P-glycoprotein (P-gp; ABCB1) [1], an intestinal efflux pump that eliminates endogenous and xenobiotic substrates (including a number of chemotherapy drugs) from the body. Overexpression of P-gp by some cancers mediates resistance to chemotherapeutics. Blocking P-gp efflux is proposed as a mechanism to improve the oral bioavailability of poorly soluble chemotherapy drugs such as irinotecan and paclitaxel. Encequidar is minimally absorbed which means that it acts principally at its preferred site of action in the intestine, and has negligible systemic exposure.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 13
Hydrogen bond donors 1
Rotatable bonds 12
Topological polar surface area 135.88
Molecular weight 688.73
XLogP 2.64
No. Lipinski's rules broken 3
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COC1=CC2=C(C=C1OC)CN(CCC3=CC=C(C=C3)N4N=C(C5=C(C=C(C(=C5)OC)OC)NC(=O)C6=CC(=O)C7=C(C=CC=C7)O6)N=N4)CC2
Isomeric SMILES O=C(C1=CC(C=2C=CC=CC2O1)=O)NC=3C(C4=NN(N=N4)C5=CC=C(CCN6CC=7C=C(C(OC)=CC7CC6)OC)C=C5)=CC(=C(C3)OC)OC
InChI InChI=1S/C38H36N6O7/c1-47-32-17-24-14-16-43(22-25(24)18-33(32)48-2)15-13-23-9-11-26(12-10-23)44-41-37(40-42-44)28-19-34(49-3)35(50-4)20-29(28)39-38(46)36-21-30(45)27-7-5-6-8-31(27)51-36/h5-12,17-21H,13-16,22H2,1-4H3,(H,39,46)
InChI Key AHJUHHDDCJQACA-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Encequidar (HM30181) is under clinical evaluations as an adjunct to chemotherapy drugs including paclitaxel and irinotecan. The addition of encequidar is predicted to facilitate the oral administration of these previously intravenously infused drugs.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02250157 A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1 Interventional Athenex, Inc.
NCT04180384 A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients Phase 2 Interventional Athenex, Inc.
NCT02594371 Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer Phase 3 Interventional Athenex, Inc.